11,848 people responded to the Government’s consultation on the licensing of non-surgical cosmetic procedures in England.
One result showed just how divided the aesthetics sector has become.
Among healthcare professionals working in cosmetics, 92% supported restricting specified high-risk procedures to suitably qualified and regulated healthcare professionals.
Among aesthetic practitioners, 62% disagreed with that restriction.
Those statistics could easily become ammunition for another medic-versus-non-medic argument.
But perhaps that’s exactly what the aesthetics industry doesn’t need.
Because professional title is only one part of patient safety.
Training matters.
Experience matters.
Anatomical knowledge matters.
Patient selection matters.
Informed consent matters.
Knowing when not to treat matters.
Complication recognition matters.
Appropriate prescribing matters.
Aftercare matters.
Product provenance and traceability matter.
And there is another part of this debate that receives far less scrutiny:
the businesses supplying the products.
At Longeva Pharma, we support appropriately trained and responsible practitioners from both medical and non-medical backgrounds.
We also believe that if the UK aesthetics industry wants higher standards, everyone involved needs to be part of that conversation — including pharmacies and suppliers like us.
So perhaps it’s time to stop asking only:
“Medic or non-medic?”
And start asking:
“What does professional aesthetic practice actually look like?”
The Numbers Behind Britain’s Aesthetics Divide
The Government consultation on licensing non-surgical cosmetic procedures in England received 11,848 responses.
Of 6,431 professional respondents asked whether they currently administered non-surgical cosmetic procedures, 5,268 — 82% — said yes.
When respondents were asked about restricting specified high-risk procedures, the divide became particularly clear.
Among healthcare professionals working in cosmetics, 92% supported restricting specified high-risk procedures to qualified and regulated healthcare professionals.
Among aesthetic practitioners, 62% disagreed.
Overall, 63% of respondents supported the proposed restriction.
These figures don’t tell us which “side” is right.
They demonstrate something more useful: different parts of the aesthetics workforce have fundamentally different views about how competence and procedural risk should be regulated.
The Government has subsequently maintained a risk-based approach to regulation rather than treating every cosmetic procedure as though it presents the same level of risk.
And that distinction matters.
What Is Actually Changing in England?
There is already a lot of misinformation surrounding UK aesthetics regulation.
So it is important to distinguish current law, Government policy and proposals that have not yet taken legal effect.
Section 180 of the Health and Care Act 2022 created the legal power for regulations to establish a licensing regime for specified cosmetic procedures in England.
The Government subsequently consulted on how such a system could operate.
In that consultation, 61% of respondents supported a three-tier classification system based on procedural risk. The Government’s response said the findings reinforced its view that a tiered system based on risk and invasiveness was an appropriate and proportionate structure for regulatory oversight.
The Government has stated its intention to proceed with a risk-based framework.
But proposed elements of the future licensing regime should not be presented as though they are all already law.
That distinction is crucial when practitioners encounter claims about aesthetics licensing in England online.
Why Is This Conversation Becoming More Urgent?
Because pressure for reform has not disappeared.
On 11 September 2026, the House of Commons Women and Equalities Committee warned that delays in Government action on high-risk cosmetic procedures were prolonging a significant risk to patient safety.
The Committee reiterated calls for immediate restrictions around the highest-risk procedures and specialist training for practitioners undertaking invasive surgical cosmetic procedures.
That deserves serious attention.
But there is an important distinction:
Arguing for additional controls around particularly high-risk procedures is not the same as arguing that non-medical practitioners should have no place in aesthetics.
Those positions should not be conflated.
Does Being a Healthcare Professional Automatically Make Someone an Excellent Aesthetic Practitioner?
Healthcare professionals can enter aesthetics with important clinical foundations.
Medicine, nursing, dentistry and pharmacy can provide education and experience in areas including anatomy, physiology, medicines, clinical assessment, safeguarding and professional accountability.
Those foundations matter.
But aesthetic medicine is also a specialised area.
A professional registration does not remove the need for procedure-specific education, supervised experience, continuing professional development or recognition of the limits of individual competence.
And the reverse is equally important.
A non-medical practitioner may have invested years in aesthetic education, anatomy training, supervised practice and continuing professional development.
But experience alone doesn’t remove the need for robust patient assessment, appropriate escalation pathways or recognition of situations requiring medical intervention.
So this should never become:
Medic = good. Non-medic = bad.
Nor should it become:
Experience = everything. Medical training = irrelevant.
Both arguments are too simplistic.
The Better Question
Can the practitioner demonstrate the knowledge, competence, judgement and systems appropriate to the procedure they are performing?
That question is considerably harder.
It is also considerably more useful.
What Did Consultation Respondents Say Mattered?
Among people reporting experience of non-surgical cosmetic procedures, 94% of 9,032 respondents said they were satisfied with the outcome of their procedures.
And 93% of 9,024 respondents said they were satisfied with their practitioner.
When respondents described positive experiences, recurring themes included:
- thorough consultations;
- informed consent;
- evidence of qualifications;
- clear communication;
- detailed medical-history reviews;
- comprehensive aftercare; and
- accessible post-treatment support.
Importantly, the Government’s analysis recorded both positive and negative experiences involving healthcare professionals and aesthetic practitioners.
That doesn’t mean professional background is irrelevant.
It demonstrates why a job title alone cannot tell us everything about the standard of a patient’s experience.
Complications Don’t Care About Professional Titles
Non-surgical does not mean risk-free.
Negative experiences reported through the Government consultation included swelling, bruising, pain, infection, scarring, filler migration and vascular occlusion.
That is why professional practice cannot simply mean knowing how to perform a treatment.
A responsible practitioner should understand:
- the relevant anatomy;
- patient suitability;
- contraindications;
- the risks associated with the treatment;
- appropriate informed consent;
- complication recognition;
- their own limitations; and
- what escalation pathway exists when something falls outside their competence.
Sometimes the most professional clinical decision isn’t knowing how to inject.
It’s knowing when not to inject.
Related practitioner guidance: Injectable Aftercare · Aesthetic Prescription Errors
But Are We Scrutinising the Wrong End of the Syringe?
Here is where this conversation becomes uncomfortable for more than practitioners.
Much of the aesthetics debate focuses on the person holding the syringe.
But before a product reaches a patient, numerous decisions have already been made.
What was ordered?
Where did it come from?
Who supplied it?
Can it be traced?
Has it been handled and stored appropriately?
And, where a prescription-only medicine is involved, have the applicable prescribing and supply requirements been followed?
These are not minor administrative details.
They are part of professional practice.
Patient Safety Doesn’t Begin When the Needle Touches the Skin
It begins with decisions made long before the patient walks through the clinic door.
And that means we need to talk about suppliers.
PRACTITIONER RESOURCE
POM ORDERING & PRACTITIONER VERIFICATION →
AESTHETIC PRESCRIPTION ERRORS →
Are Aesthetic Suppliers Part of the Problem Too?
Practitioners are constantly being told standards must rise.
Train more.
Improve governance.
Document more.
Improve consultations.
Understand complications.
Provide better aftercare.
Source responsibly.
Those expectations are legitimate.
But professional standards cannot be the responsibility of practitioners alone.
The businesses supplying the industry influence the market too.
And aesthetics has become extraordinarily price competitive.
Practitioners can be exposed to flash sales, bulk-buy incentives, constant discount codes, price-matching and marketing whose primary message is simply:
GO LOWER.
Lower price.
Bigger discount.
More units.
There is absolutely nothing wrong with competitive pricing.
Clinics are businesses. Margins matter.
Practitioners should compare prices and expect suppliers to remain commercially competitive.
Longeva Pharma competes on price too.
And a cheaper product is not automatically inferior.
Equally, an expensive supplier is not automatically a better supplier.
But there is a fundamental difference between good value and creating a market in which price becomes virtually the only measure of value.
When Did Professional Supply Become a Race to the Bottom?
This is the uncomfortable question.
If the purchasing conversation becomes dominated entirely by price, other questions risk being pushed aside.
Instead of:
“Who is supplying this product?”
the question becomes:
“Who has it cheapest today?”
Instead of:
“Can I trace its provenance?”
it becomes:
“What’s the discount code?”
Instead of:
“What service and accountability sit behind this supplier?”
it becomes:
“Can somebody beat this price?”
That doesn’t mean buying competitively is irresponsible.
It means price should be one component of a professional purchasing decision — not a substitute for one.
A Dermal Filler Isn’t Just Another SKU
Aesthetic products cannot always sensibly be treated in the same way as ordinary consumer goods.
And prescription medicines certainly cannot.
Different products carry different regulatory requirements.
But there are basic questions every professional clinic should be comfortable asking:
Who am I buying from?
Where has the product come from?
Can it be traced?
How has it been handled?
What happens if there’s a problem?
Can I speak to someone?
Does this supplier understand the professional sector it serves?
Know Your Product. Know Your Supplier.
The aesthetics industry talks extensively about practitioner accountability.
Supplier accountability belongs in that conversation too.
Suppliers Cannot Demand Higher Standards While Ignoring Their Own
And this is where Longeva Pharma has to be willing to apply the argument to itself.
It would be easy for any pharmacy or supplier to publish an article telling practitioners to improve.
That’s not enough.
If suppliers expect practitioners to operate professionally, we should expect professional standards from ourselves too.
We should be asking:
Are we building long-term professional relationships or simply shifting units?
Are appropriate controls being applied to the products we supply?
Can practitioners speak to knowledgeable people when they need assistance?
Are we helping customers understand responsible sourcing?
Are we competing responsibly?
Are we offering something beyond today’s discount?
And are we willing to be accountable for the part of the supply chain we control?
Those questions apply to Longeva Pharma just as much as they apply to everybody else.
The Longeva Pharma Position — Value Without a Race to the Bottom
We want to be competitive.
We want our customers to receive excellent value.
And where we can give practitioners a stronger commercial proposition, we will.
But we don’t believe “cheap” should be the entire relationship between a professional practitioner and their supplier.
Our proposition is broader.
Competitive pricing.
Professional supply.
Traceability.
Reliable fulfilment.
Practitioner-focused service.
Knowledgeable support.
And real people practitioners can build a relationship with.
For eligible practitioners across Greater Manchester, this can also include same-day delivery or pre-arranged local collection, subject to practitioner approval, prescription requirements, stock availability and confirmation when ordering. Longeva Pharma’s existing same-day service explicitly covers botulinum toxins and diluents for eligible practitioners.
Need Stock Today in Greater Manchester?
EXPLORE SAME-DAY DELIVERY & COLLECTION →
So perhaps the question shouldn’t simply be:
“How cheap can you make it?”
It should also be:
“What am I getting from the business I’m trusting to supply my clinic?”
Professional Supply for Medical and Non-Medical Practitioners
Longeva Pharma supports appropriately trained and responsible practitioners from medical and non-medical backgrounds.
OPEN A LONGEVA PHARMA PRACTITIONER ACCOUNT →
Professional Pharmacy Supply
For eligible professional customers, Longeva Pharma provides access to its specialist aesthetics-pharmacy range, subject to the applicable practitioner verification, prescribing and pharmacy requirements.
OPEN YOUR PRACTITIONER ACCOUNT →
Explore the Main Botulinum Toxin Ranges
Buy BOTOX · Buy Azzalure · Buy Alluzience · Buy Relfydess · Buy BOCOUTURE · Buy Letybo · Buy Nuceiva
The current Same-Day collection itself contains Letybo, Azzalure, Nuceiva, Relfydess, Alluzience, BOCOUTURE and BOTOX, so these are commercially relevant product pathways rather than arbitrary SEO links.
For practitioners comparing the medicines, also read:
BOTOX vs Azzalure vs BOCOUTURE vs Letybo vs Alluzience vs Relfydess →
Could Better Regulation Actually Benefit Responsible Practitioners?
Regulation is often discussed only as a restriction.
There is another perspective.
Responsible practitioners already invest significant amounts of time and money into doing things properly:
Training.
Insurance.
Suitable premises.
Consultations.
Consent.
Professional products.
Documentation.
Aftercare.
Continuing professional development.
Complication pathways.
Responsible sourcing.
Those investments have a cost.
A proportionate regulatory framework that establishes meaningful minimum standards could potentially make it easier for patients to distinguish between practitioners who have invested in professional practice and those who have not.
But proportionate is the important word.
Regulation should address genuine risks.
It should recognise that different procedures carry different levels of risk.
And responsible voices from both medical and non-medical aesthetics should be part of that discussion.
The Standards That Should Unite Medics and Non-Medics
There will continue to be disagreement about who should perform particular procedures.
That’s legitimate.
But there should be far more that responsible practitioners agree on than divides them.
Patients deserve:
- honest consultations;
- appropriate treatment recommendations;
- informed consent;
- practitioners working within their competence;
- appropriate aftercare;
- clear complication pathways;
- appropriately sourced and traceable products; and
- accountability when something doesn’t go according to plan.
None of those principles requires the industry to divide itself into tribes.
Perhaps “Medic or Non-Medic?” Is the Wrong First Question
Instead, ask:
What are you trained to do?
Can you demonstrate competence in the procedure you’re offering?
Do you understand the relevant anatomy and risks?
Do you know your limitations?
How do you assess your patients?
How do you obtain informed consent?
What happens if there is a complication?
Are you appropriately insured?
Where do your products come from?
Can you trace them?
Who supplies them?
And where a prescription-only medicine is involved:
Are the appropriate prescribing and supply requirements being followed?
Those questions tell us considerably more about professional practice than an argument on social media ever will.
Professional Aesthetics Requires Professional Standards From Everyone
Perhaps the biggest mistake in the medic-versus-non-medic debate is believing that the person holding the syringe is the only person whose standards matter.
They aren’t.
The practitioner matters.
The prescriber matters.
The training provider matters.
The pharmacy matters.
The supplier matters.
The manufacturer matters.
And the systems connecting all of them matter.
At Longeva Pharma, we support appropriately trained and responsible practitioners from both medical and non-medical backgrounds.
We support proportionate regulation that protects patients and raises meaningful standards.
We support competitive pricing.
But we don’t believe the future of professional aesthetics should become a race to see who can shout “CHEAPEST” the loudest.
Because professional standards don’t begin when the needle enters the skin.
They begin with every decision made before it does.
And they continue long after the treatment has finished.
Your Supplier Is One of Those Decisions
Choose on price.
But don’t choose on price alone.
Know your product.
Know its provenance.
Know your responsibilities.
Know your supplier.
Longeva Pharma
Professional supply. Competitive pricing. Personal service.
Supporting appropriately trained medical and non-medical aesthetic practitioners.
OPEN YOUR PRACTITIONER ACCOUNT →
Related Longeva Pharma practitioner resources
Explore Longeva Pharma on Faces; toxin product and service directory; Faces Consent practitioner guide. Prescription-only medicines require appropriate verification, prescribing and dispensing; same-day availability depends on location, timing and stock.